Three advances necessary to bring dolastatin 16 (1) into full-scale preclinical development as an anticancer drug have been accomplished. The X-ray crystal structure of dolastatin 16 has been solved, which allowed stereoselective syntheses of its two new amino acid units, dolamethylleuine (Dml) and dolaphenvaline (Dpv), to be completed. The X-ray crystal structures of synthetic Z-Dml and TFA-Dpv have also been completed.
Three advances necessary to bring dolastatin 16 (1) into full-scale preclinical development as an antin class="Disease">cancer drug have been accomplished. The X-ray crystal structure of dolastatin 16 has been solved, which allowed stereoselective syntheses of its two new amino acid units, dolamethylleuine (Dml) and dolaphenvaline (Dpv), to be completed. The X-ray crystal structures of synthetic Z-Dml and TFA-Dpv have also been completed.
Authors: Tanja Woyke; Robert W Roberson; George R Pettit; Günther Winkelmann; Robin K Pettit Journal: Antimicrob Agents Chemother Date: 2002-12 Impact factor: 5.191
Authors: Ekatherine M Prokopiou; Patricia A Cooper; George R Pettit; Michael C Bibby; Steven D Shnyder Journal: Mol Med Rep Date: 2010 Mar-Apr Impact factor: 2.952
Authors: G G Harrigan; W Y Yoshida; R E Moore; D G Nagle; P U Park; J Biggs; V J Paul; S L Mooberry; T H Corbett; F A Valeriote Journal: J Nat Prod Date: 1998-10 Impact factor: 4.050
Authors: Tanja Woyke; Michael E Berens; Dominique B Hoelzinger; George R Pettit; Günther Winkelmann; Robin K Pettit Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss Journal: Med Res Rev Date: 2016-12-07 Impact factor: 12.944